One year later, the results from the EMPOWER-Lung 3 phase III study provided further support for the routine administration of cemiplimab plus platinum-based chemotherapy, as a first-line option for NSCLC with high PD-L1 expression (Table 1) [51]. Here, CD274 is linked to non-small cell lung carcinoma.